GOLD Guidelines 2022 Updates: A Review for Pharmacists Across Multiple Practice Settings

Program Description

Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease worldwide that is associated with significant health and economic burden. It is the third leading cause of mortality worldwide, causing 3.2 million deaths in 2019. In the United States, more than 26 million people are estimated to have COPD, but almost half of these individuals remain undiagnosed. Several classes of medications are used for the treatment of COPD; the choice within each class depends on the availability and cost of the drug, and clinical efficacy and safety profile. However, even with maximal inhaled therapies, many patients remain symptomatic and functionally impaired. Effective COPD management includes early diagnosis, individualized therapy selection, and ongoing patient education to optimize inhaler use and adherence. Several studies have demonstrated the impact of pharmacist-led interventions to improve outcomes in patients with COPD. Pharmacists should be knowledgeable about the 2022 update of the Global Initiative for Chronic Obstructive Lung Disease report, including evidence-based recommendations for the prevention and treatment of COPD.

Target audience: Health-system pharmacists, retail pharmacists, and pharmacy technicians

Type of activity: Application for pharmacists; knowledge for pharmacy technicians
Release date: August 17, 2022
Expiration date: October 17, 2022

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

Pharmacists

• Identify the clinical challenges and barriers associated with chronic obstructive pulmonary disease (COPD), burden of the disease, and need to improve patient outcomes
• Explore the 2022 updates to the Global Initiative for Chronic Obstructive Lung Disease guidelines on COPD and management of COPD
• Examine current and emerging treatments for COPD, including their safety, efficacy, and use in specific patient populations for optimal outcomes
• Highlight the role of the pharmacist in multiple practice settings in the management of patients with COPD and providing individualized strategies and treatment recommendations

Pharmacy technicians

• Recognize the clinical challenges and barriers associated with chronic obstructive pulmonary disease (COPD), burden of the disease, and need to improve patient outcomes
• Study the 2022 updates to the Global Initiative for Chronic Obstructive Lung Disease guidelines on COPD and management of COPD
• Review current and emerging treatments for COPD, including their safety, efficacy, and use in specific patient populations for optimal outcomes
• Illustrate the role of the pharmacy technician in COPD management and optimizing the care of patients

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity numbers 0290-0000-22-348-L01-P and 0290-0000-22-349-L01-T. The activity is available for CE credit through October 17, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Rupal Mansukhani, PharmD, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms